

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (gh-177) TISOTUMAB VEDOTIN
 PRONUNCIATION tye sot' ue mab ve doe' tin
 THERAPEUTIC CLAIM Treatment of cancer

CHEMICAL NAMES

1. Immunoglobulin G1, anti-(human blood-coagulation factor III) (human monoclonal HuMax-TF heavy chain), disulfide with human monoclonal HuMax-TF κ -chain, dimer, tetrakis(thioether) with *N*-[[[4-[[*N*-[6-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-1-oxohexyl]-*L*-valyl]-*N*⁶-(aminocarbonyl)-*L*-ornithyl]amino]phenyl]methoxy]carbonyl]-*N*-methyl-*L*-valyl]-*N*-[(1*S*,2*R*)-4-[(2*S*)-2-[(1*R*,2*R*)-3-[(1*R*,2*S*)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1*S*)-1-methylpropyl]-4-oxobutyl]-*N*-methyl-*L*-valinamide
2. Immunoglobulin G1-kappa, anti-(*Homo sapiens* Tissue factor (Coagulation factor III, Thromboplastin, CD142 antigen, TF)); *Homo sapiens* monoclonal antibody; γ 1 heavy chain (1-448) [*Homo sapiens* VH (IGHV3-23*01 (94%) – (IGHD)-IGHJ5*01 (87%)) [8.8.11] (1-118) -*Homo sapiens* IGHG1*03] (119-448)], (221-214')-disulfide with κ light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1D-16*01 (97%) –IGKJ2*01)[6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')], dimer (227'-227":230-230")-bisdisulfide, *S*-substituted on an average of 3 to 4 cysteinyl, after partial reduction of the tisotumab, by vedotin radicals : (3*RS*)-1-(6-[[[(2*S*)-1-[[[(2*S*)-5-(carbamoylamino)-1-{4-[[[(2*S*)-1-[[[(2*S*)-1-[[[(3*R*,4*S*,5*S*)-1-[(2*S*)-2-[(1*R*,2*R*)-3-[(1*S*,2*R*)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl](methyl)amino)-3-methyl-1-oxobutan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]methylcarbamoyl]oxy)methyl]anilino)-1-oxopentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]amino}-6-oxohexyl)-2,5-dioxopyrrolidin-3-yl

STRUCTURAL FORMULA

| Heavy chain | | | | | |
|-------------|-------------|------------|------------|------------|------|
| EVQLLESGGG | LVQPGGSLRL | SCAASGFTFS | NYAMSWVRQA | PGKGLEWVSS | 50 |
| ISGSGDYTTY | TDSVKGRFTI | SRDNSKNTLY | LQMNSLRAED | TAVYYCARSP | 100 |
| WGYLDSWQQ | GTLVTVSSAS | TKGPSVFPLA | PSSKSTSGGT | AALGCLVKDY | 150 |
| FPEPVTVSWN | SGALTSGVHT | FPAVLQSSGL | YSLSSVTVTP | SSSLGTQTYI | 200 |
| CNVNHKPSNT | KVDKRVPEPKS | CDKTHTCPPC | PAPELLGGPS | VFLFPPKPKD | 250 |
| TLMISRTPEV | TCVVVDVSHE | DPEVKFNWYV | DGVEVHNAKT | KPREEQYNST | 300 |
| YRVVSVLTVL | HQDWLNGKEY | KCKVSNKALP | APIEKTISKA | KGQPREPQVY | 350 |
| TLPPSREEMT | KNQVSLTCLV | KGFYPSDIAV | EWESNGQPEN | NYKTTTPVLD | 400 |
| SDGSFFLYSK | LTVDKSRWQQ | GNVFSCSVHM | EALHNHYTQK | SLSLSPGK | 448 |
| Light chain | | | | | |
| DIQMTQSPPS | LSASAGDRVLT | ITCRASQGIS | SRLAWYQQKP | EKAPKSLIYA | 50' |
| ASSLQSGVPS | RFSGSGSGTD | FTLTISLQ | EDFATYYCQQ | YNSYPYTFGQ | 100' |
| GTKLEIKRTV | AAPSVFIFPP | SDEQLKSGTA | SVVCLLNNFY | PREAKVQWKV | 150' |
| DNALQSGNSQ | ESVTEQDSKD | STYLSSTLT | LSKADYEKHK | VYACEVTHQG | 200' |
| LSSPVTKSFN | RGEC | | | | 214' |

